| Name | Title | Contact Details |
|---|
Polymedco Inc. is a Cortlandt Manor, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Providence Clinical Research is a Burbank, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioVentrix is a privately held medical device company headquartered in San Ramon, CA, USA.
Inogen`s mission to improve the quality of life of supplemental oxygen users began in 2001 when Mae, a beloved Grandmother, was prescribed oxygen therapy. Learn more about Mae`s Story here: http://www.inogen.com/about-inogen/meet-mae/. Inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. We estimate that more than 2.5 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy. Our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. We believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. With each step we take to improve our products and service, our customers take another step toward more freedom.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.